 |
 |
| January 27, 2012 |
Proteonomix, Inc. |
 |
PROTEONOMIX, INC.'s (PROT) CEO to Present at Investor Summit 2012 Sponsored by Merriman Capital in New York on February 1, 2012. |
 |
MOUNTAINSIDE, NJ--(Marketwire -01/27/12)- PROTEONOMIX, INC. (OTC.BB: PROT.OB - News), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it will be presenting at the Investor Summit 2012 on February 1, 2012, sponsored by Merriman Capital at the Intercontinental Time Square Hotel in New York City. |
|
| Read Full Story > |
|
 |
| January 4, 2012 |
Proteonomix, Inc. |
|
Proteonomix, Inc. (PROT) Announces IRB Approval for Its Clinical Trial of UMK-121 in Patients With End Stage Liver Disease. |
|
MOUNTAINSIDE, NJ--(Marketwire -01/04/12)- Proteonomix, Inc. (OTC.BB: PROT.OB - News), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that the Company's clinical trial of UMK-121 has received IRB (Institutional Review Board) approval and is now ready for the recruitment of patients. |
|
| Read Full Story > |
|
